Kazakhstan's vaccine ready for human clinical trials

AKIPRESS.COM - Scientists in Kazakhstan completed preclinical trials of inactivated vaccine against COVID-19 on the basis of the National Center for Examination of Medicines and Medical Devices in Almaty. The vaccine has been tested for safety and toxic effects on animals.
The level of vaccine safety was confirmed by hematological and biochemical blood parameters. Scientists also assessed the effects of the vaccine on organs of animals.
The preclinical trials showed that COVID-19 vaccine is non-toxic and can be tested on human volunteers.
"We need further large-scale clinical trials to fully assess the safety and effectiveness of the new vaccine. It will be possible to speak about vaccine safety only after all the research," said Valentina Shnaukshta, head of the Almaty laboratory for pharmacological tests at the center.
All experiments were performed in the vivarium of the National Center for Examination of Medicines and Medical Devices.
The laboratory for pharmacological research has the status of international accreditation of the Slovak National Accreditation Service (SNAS) for compliance with GLP OECD and is the only laboratory in Kazakhstan to conduct bioequivalence studies.
The World Health Organization earlier registered the vaccine of Kazakh scientists and included it in the list of candidate vaccines against COVID-19, which are allowed for preclinical studies.
The inactivated vaccine was developed by the Scientific Research Institute of Biological Safety Problems of the Science Committee of the Ministry of Education and Science in Kazakhstan. According to the Ministry, vaccine was created on the basis of a virus strain taken from local patients.